| 引用本文: | 姜丽钰,俞凌燕,周亚娇,陈芝兰,许东航.司美替尼治疗Ⅰ型神经纤维瘤病的药学专家共识[J].中国现代应用药学,2026,43(19):121-133. |
| Jiang Liyu,Yu Lingyan,Zhou Yajiao,Chen Zhilan,Xu Donghang.Expert Consensus on the Pharmacotherapy of Selumetinib in Neurofibromatosis Type 1[J].Chin J Mod Appl Pharm(中国现代应用药学),2026,43(19):121-133. |
|
| 摘要: |
| Ⅰ型神经纤维瘤病(neurofibromatosis type 1, NF1)是由NF1基因突变引起的常染色体显性遗传病,可累及多个系统。丛状神经纤维瘤(plexiform neurofibroma, PN)是NF1的常见临床表现之一,可引发致残、致畸以及恶变,严重危害患者生命健康。司美替尼(selumetinib)作为一种选择性MEK1/2抑制剂,对无法手术的PN-NF1患者具有良好的治疗效果。目前,国内关于司美替尼的临床使用经验较为有限。为进一步规范其在临床中的应用,浙江省药学会循证药学专业委员会联合浙江省医师协会临床合理用药专业委员会组织国内多学科专家学者,基于国内外最新循证证据,围绕司美替尼的临床应用、给药方案、血药浓度监测、药物相互作用、特殊人群用药和不良反应、超剂量用药及中毒处置等方面,形成6条推荐意见,旨在为临床医生和药师提供全面指导,以保障PN-NF1患者用药安全,改善预后。 |
| 关键词: 司美替尼 Ⅰ型神经纤维瘤病 专家共识 |
| DOI: |
| 分类号: |
| 基金项目: |
|
| Expert Consensus on the Pharmacotherapy of Selumetinib in Neurofibromatosis Type 1 |
|
Jiang Liyu, Yu Lingyan, Zhou Yajiao, Chen Zhilan, Xu Donghang
|
|
The Second Affiliated Hospital,Zhejiang University School of Medicine
|
| Abstract: |
| Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder caused by mutations in the NF1 gene, affecting multiple systems. Plexiform neurofibroma (PN) is one of the common clinical manifestations of NF1, which can lead to disability, teratogenesis, and malignant transformation, severely threatening the life and health of patients. Selumetinib, a selective MEK1/2 inhibitor, has demonstrated clinical efficacy in the treatment of inoperable PN-NF1. However, clinical practice with selumetinib remains limited. To further standardize the clinical application of selumetinib, the Evidence-based Pharmacy Professional Committee of Zhejiang Pharmaceutical Association, in collaboration with the Clinical Rational Drug Use Professional Committee of Zhejiang Medical Doctor Association, convened multidisciplinary experts to develop the consensus. Based on the latest evidence, the consensus developed six recommendations covering key aspects of selumetinib use, including clinical application, dosing regimens, therapeutic drug monitoring, drug interactions, use in special populations, adverse reactions, as well as management of overdose and poisoning. These recommendations aim to provide comprehensive guidance for clinicians and pharmacists, ensuring medication safety and improving prognosis of PN-NF1. |
| Key words: selumetinib neurofibromatosis type 1 expert consensus |